Chapter 34: Antimicrobial Resistance

The chapter establishes how bacterial populations acquire resistance through genetic variation and evolutionary pressure, allowing microorganisms to adapt when exposed to antimicrobial agents. Understanding the molecular mechanisms of resistance is central to addressing this challenge. Bacteria employ several distinct strategies to neutralize antimicrobials: enzymatic degradation breaks down drugs before they can reach their targets, with beta lactamases serving as a key example of this defense mechanism. Structural modifications to bacterial cell membranes decrease drug penetration, preventing antimicrobials from reaching their sites of action. Active efflux systems pump antimicrobial compounds out of bacterial cells, maintaining sublethal concentrations inside the organism. Some bacteria bypass antimicrobial inhibition entirely by activating alternative metabolic pathways that circumvent the targeted biochemical process. Bacteria also modify the protein structures that antibiotics normally bind to, such as ribosomal binding sites and penicillin binding proteins, eliminating drug efficacy. The chapter addresses how resistance genes spread rapidly through bacterial populations via horizontal gene transfer, particularly through plasmid-mediated mechanisms that allow resistance traits to move between different species and strains. Clinical manifestations of resistance are illustrated through multidrug-resistant organisms, methicillin-resistant strains, vancomycin-resistant enterococci, and carbapenem-resistant species, each representing escalating threats to patient outcomes. The chapter concludes by discussing the selective pressure mechanisms that drive resistance development and emphasizes antimicrobial stewardship and pharmaceutical intervention strategies as essential frameworks for preserving the effectiveness of current therapeutic agents and preventing the emergence of untreatable infections.